# NOD Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nod-pharmaceuticals

- Industry: Materials
- Headquarters: San Diego, US
- Website: www.nodpharm.com
- Total disclosed funding: $6.5M
- Latest round: Series B (Dec 30, 2006)
- Investors on record: 2

## About

NOD Pharmaceuticals specializes in providing premium domain names specifically for the pharmaceutical and health-related sectors, enhancing online visibility and brand authority for businesses in these fields.NOD Pharmaceuticals focuses on digital assets in the pharmaceutical industry, offering unique domain names to enhance online presence. The company operates from its headquarters in San Diego, US. The CEO, William Lee, has a history of leading ventures in the technology and healthcare sectors. In December 2006, NOD Pharmaceuticals raised USD 5.5 million in Series B financing from BVCF Capital and China Renaissance Capital Investment, indicating strategic backing for its operations.NodPharm.com is a premium domain name available for acquisition through HugeDomains, aimed at businesses and individuals looking to enhance their online presence in the pharmaceutical sector. The domain offers a unique web address that conveys trust and authority, catering to e-commerce platforms, informational websites, and online health services. This digital asset is marketed to a global audience in North America, Europe, and Asia, focusing on companies in pharmaceuticals, wellness products, and health services.The revenue structure for NodPharm.com is based on direct sales through HugeDomains, with the domain priced at USD 595 or available through a 12-month payment plan of USD 49.58 per month, totaling USD 595 with no interest charged. The purchasing process is straightforward, granting access to the domain within one to two hours after the transaction, appealing to entrepreneurs and businesses seeking a strategic digital address.NOD Pharmaceuticals aims to leverage its recent funding of USD 5.5 million from December 2006 to enhance its product offerings and expand into new markets. The company plans to develop new domain names tailored for emerging health sectors and is targeting expansion into Asia by the end of 2024. The recent investment will support these initiatives, allowing the company to increase its market reach and improve its service offerings.

## Funding rounds

- Series B, Dec 30, 2006, $5.5M — China Renaissance Capital Investment, BVCF Capital
- Series A, May 1, 2005, $1M — BVCF Capital

## Investors

- BVCF Capital — Series A, Series B
- China Renaissance Capital Investment (https://capitalatlas.ai/funds/china-renaissance-capital-investment) — Series B